Dubai PR Network, Online Press Release from Dubai and Middle East
Medicine, Laboratory & Treatment(Healthcare & Medicine)
Filter PR by
Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease Progression

Endoscopic ablation in patients with Barrett's esophagus containing confirmed low-grade dysplasia reduces the relative risk for disease progression by 94% as compared to controls

ORLANDO, Fla.-May 22, 2013-(BUSINESS WIRE/ ME NewsWire)-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using the Barrx™ RF Ablation System is effective at eliminating Barrett's esophagus, a pre-cancerous condition of the esophagus, and preventing disease progression.

The SURF Trial* (SUrveillance vs. RadioFrequency ablation) included 136 patients with Barrett's esophagus containing confirmed low-grade dysplasia. Upon enrollment, patients were randomly assigned to receive either endoscopic ablation therapy and subsequent endoscopic observation (treatment group) or endoscopic observation alone (control group). Tissue samples (biopsies) were obtained at regular intervals after enrollment to assess for the presence of Barrett's tissue, dysplasia and esophageal cancer.

The primary endpoint of the trial was a comparison of the risk of disease progression over time between the ablation and control groups. Disease progression was defined as the development of either high-grade dysplasia or esophageal cancer during follow-up. The authors reported that endoscopic ablation therapy resulted in a 94% relative risk reduction in disease progression, compared to controls (1.5% progression in ablation group vs. 25.0% progression in control group) over a two-year follow-up period.

Other endpoints included resolution of Barrett's tissue and occurrence of adverse events. At last endoscopy visit, 90% of patients treated with ablation were free of all signs of Barrett's esophagus tissue, while none of the patients in the control group demonstrated resolution of Barrett's tissue. The most common adverse event was esophageal narrowing in the ablation group, which occurred in 7 patients (10.3%) and was resolved with endoscopic dilation.

“In patients with Barrett's esophagus containing confirmed low-grade dysplasia, endoscopic ablation significantly reduced disease progression to high-grade dysplasia and esophageal cancer, as compared to surveillance alone,” said principal investigator Jacques Bergman, M.D., Ph.D., Professor of Gastrointestinal Endoscopy, Director of Endoscopy, Academic Medical Center, Amsterdam, the Netherlands. “The difference in the disease progression outcome between the two groups was so large, in fact, that the data safety monitoring board overseeing the trial recommended early stoppage of the trial, and patients in the control group will now be offered endoscopic ablation.”

The study, entitled “Radiofrequency Ablation in Barrett's Esophagus with Confirmed Low-Grade Dysplasia: Results of a European Multicenter Randomized Controlled Trial (SURF),” was conducted at nine European medical centers with expertise in the management of Barrett's esophagus, dysplasia and cancer. Dr. Bergman's colleague, Kai Yi N. Phoa, M.D., presented the outcomes data yesterday (Abstract #1004) at Digestive Disease Week 2013, part of an American Gastroenterological Association research forum held here this week.

“This trial adds very important new information to the management algorithm for patients with Barrett's esophagus containing confirmed low-grade dysplasia,” commented David S. Utley, M.D., Chief Medical Officer, Covidien GI Solutions. “Until now, there was some level of uncertainty regarding the optimal management strategy for a patient with low-grade dysplasia. We believe that this randomized, controlled trial provides the highest level of evidence that disease progression in this population is high over two years when observation alone is employed, and that this progression risk can be significantly reduced if the patient is treated proactively with endoscopic ablation.”

Barrett's esophagus develops as a result of chronic injury from gastroesophageal reflux disease. The normal esophageal lining is replaced with abnormal cells (Barrett's tissue), predisposing the patient to a risk for developing adenocarcinoma (cancer) of the esophagus. Patients with Barrett's who ultimately develop cancer typically do so through a series of steps, starting with early Barrett's, proceeding to low-grade dysplasia or high-grade dysplasia and then, finally, progressing to cancer.
*The SURF Trial was supported by funds, products and collaboration provided by Covidien.

About CovidienCovidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.
*source: ME NewsWire

The release can be read online:

Posted by : Dubai PR Network Editorial Team
Viewed 10468 times
PR Category : Healthcare & Medicine
Posted on : Thursday, May 23, 2013  2:26:00 PM UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of
Previous Story : DNA workshops to be presented by forensic scientist at Bahra...
Email this article Print this article

Share this article with your friends and followers
Back to Section Home

Related Stories

Most Viewed Press Release posted in the last 7 days
Inventive, Futuristic and Daring Translucent is a Distinguished Milestone for Police. [7960-Views]
Introducing Lunette: A Tool to Empower Women [5838-Views]
Show your Nanny some love and treat them to a Complimentary Haircut throughout August and ... [5508-Views]
Corum Golden Bridge Titane DLC - black beauty for the man of style [5057-Views]
Same Favourite Fragrance, New Innovative Products From the Ritual of Karma [4490-Views]
Robinsons Showcases Malone Souliers' Stunning New Collection for Pre-Fall 19 [4441-Views]
Tazio Nuvolari Vanderbilt Cup [4435-Views]
Aesop's Parsley Seed Skin Priming Regimen [4410-Views]
Dubai Delivers on Tourist Volumes Again, With a Strong 8.36 Million Overnight Visitors in ... [4362-Views]
Marks & Spencer Unveils Its Autumn 2019 Kidswear Collection [4172-Views]
GEMS Education students shine with excellent A-Level examination results [4136-Views]
Ferragamo Urban - 2019 Fall/Winter Collection [4075-Views]
Scafograf Black Sheep - unconventionally exceptional [3995-Views]
Autumn / Winter 2019-20 Men's and Women's Sneakers Collection [3983-Views]
Corum Admiral Legend 42-Icon ahead [3941-Views]
Exceptional Playtime with Soundcore Vortex [3855-Views]
GUESS - The Perfect Tote [3819-Views]
Sandro: The Power Suit [3812-Views]
The Nordic Hall of the Heros is Open for Business - Aston Martin Valkyrie and Valhalla Tak... [3721-Views]
Al Ain Hospital doctors save young girl from 2.5 cm pin in her lungs [3666-Views]
Hormann announces speed rolling shutter DD S6 [3623-Views]
Second Week of “Health & Tourism 2019” Campaign Witnesses Remarkable Participation in its ... [3605-Views]
Ralph Lauren Debuts “Wear Your Story” Denim Campaign [3605-Views]
The future of photography and videography is in Canon's hands, with five 2019 EISA Awards [3599-Views]
Get 50 per cent off back-to-school essentials at Dragon Mart [3575-Views]
RSS Facebook Twitter LinkedDin
Top Sections
Top Stories